Tumour immunology

Tumour immunology describes the interaction between cells of the immune system with tumour cells. Understanding these interactions is important for the development of new therapies for cancer treatment.

Latest Research and Reviews

  • Research | | open

    Agonistic 4-1BB antibodies developed for cancer immunotherapy have suffered from either hepatotoxicity or insufficient anti-cancer activity. Here the authors determine the contribution of FcγR binding and agonistic strength to these outcomes, and engineer a 4-1BB antibody with potent anti-tumor effect and no liver toxicity in mice.

    • Xinyue Qi
    • , Fanlin Li
    • , Yi Wu
    • , Chen Cheng
    • , Ping Han
    • , Jieyi Wang
    •  & Xuanming Yang
  • Research | | open

    LNK is a tumor suppressor in hematopoietic cancers, but its function in melanoma is unclear. Here, the authors show that the overexpression of LNK in melanomas correlate with hyperactive signaling of the RAS-RAF-MEK pathway and LNK enhances melanoma growth and survival and immune evasion by inhibiting IFN signalling.

    • Ling-Wen Ding
    • , Qiao-Yang Sun
    • , Jarem J. Edwards
    • , Lucia Torres Fernández
    • , Xue-Bin Ran
    • , Si-Qin Zhou
    • , Richard A. Scolyer
    • , James S. Wilmott
    • , John F. Thompson
    • , Ngan Doan
    • , Jonathan W. Said
    • , Nachiyappan Venkatachalam
    • , Jin-Fen Xiao
    • , Xin-Yi Loh
    • , Maren Pein
    • , Liang Xu
    • , David W. Mullins
    • , Henry Yang
    • , De-Chen Lin
    •  & H. Phillip Koeffler
  • Reviews |

    This Opinion article provides an overview of the mechanisms that regulate sensitivity to ferroptosis in cancer cells and how the modulation of metabolic pathways controlling ferroptosis might reshape the tumour niche, leading to an immunosuppressive microenvironment that promotes tumour progression.

    • José Pedro Friedmann Angeli
    • , Dmitri V. Krysko
    •  & Marcus Conrad
  • Research |

    Disruption of the CARMA1–BCL10–MALT1 (CBM) signalosome causes Treg cells to produce IFNγ and develop dominant anti-tumour activity in synergy with anti-PD-1 treatment, and in the absence of autoimmunity.

    • Mauro Di Pilato
    • , Edward Y. Kim
    • , Bruno L. Cadilha
    • , Jasper N. Prüßmann
    • , Mazen N. Nasrallah
    • , Davide Seruggia
    • , Shariq M. Usmani
    • , Sandra Misale
    • , Valentina Zappulli
    • , Esteban Carrizosa
    • , Vinidhra Mani
    • , Matteo Ligorio
    • , Ross D. Warner
    • , Benjamin D. Medoff
    • , Francesco Marangoni
    • , Alexandra-Chloe Villani
    •  & Thorsten R. Mempel
    Nature, 1-5
  • Reviews |

    Tertiary lymphoid structures (TLSs) form outside of lymphoid tissues at sites of chronic inflammation, including tumours. This Review describes the evidence demonstrating that TLSs are critical for generating antitumour immune responses and are associated with better prognosis in certain cancer types. It also presents potential strategies aimed at inducing TLS neogenesis to improve clinical responses in poorly immunogenic cancers.

    • Catherine Sautès-Fridman
    • , Florent Petitprez
    • , Julien Calderaro
    •  & Wolf Herman Fridman

News and Comment